---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-22-000154"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:16:32.021642+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio reports Q3 net income $20.5M, announces merger with Carisma Therapeutics

## Summary
- Merger with Carisma: Sesen stockholders own ~41.7%, Carisma ~58.3% of combined company with ~$180M cash.
- Sesen stockholders to receive CVR for potential Roche payments related to EBI-031 asset sale.
- Combined company led by Carisma management; focus on CAR-M therapies for cancer.
- Q3 revenue $40M from Roche asset sale; net income $20.5M ($0.10 per diluted share).
- Cash $184.9M as of Sep 30, 2022; restructuring charges $10.9M from pausing Vicineum development.

## SEC filing metadata
- accession: 0001485003-22-000154
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/0001485003-22-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/sesnform3q2022earningsrele.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-22-000154
- JSON: https://secwatch.observer/filing/0001485003-22-000154.json
- Plain text: https://secwatch.observer/filing/0001485003-22-000154.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported the third quarter ended September 30, 2022 results: revenue $40.0 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $40.0 million
  - Result: reported results
  source text: 30, 2022, compared to cash and cash equivalents of $162.6 million as of December 31, 2021. • Total Revenue: Total revenue for the three months ended September 30, 2022 was $40.0 million, which was due to the execution of the Roche Asset Purchase Agreement. • R&D Expenses: Research and development expenses were $2.9 million for the three months ended September
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/0001485003-22-000154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.